Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Keybanc Downgrades Ballys to Sector Weight

Keybanc analyst Brett Andress downgrades Ballys (NYSE:BALY) from Overweight to Sector Weight.

byBenzinga Newsdesk

March 3, 2022

1 minute read

Keybanc analyst Brett Andress downgrades Ballys (NYSE:BALY) from Overweight to Sector Weight.

JP Morgan Upgrades Continental Resources to Overweight, Announces $46 Price Target

By Benzinga Newsdesk

Today, 5:08 AM

JP Morgan analyst Arun Jayaram upgrades Continental Resources (NYSE:CLR) from Neutral to Overweight and announces $46 price target.

CLR

FDA Okays bluebird bio’s $3M Gene Therapy For Rare Neurological Disorder In Boys: What Investors Should Know

By Shanthi Rexaline

Today, 5:08 AM

Biotechnology company, bluebird bio, Inc. (NASDAQ: BLUE) announced late Friday that the Food and Drug Administration approved its gene therapy for a rare neurodegenerative disease.

BLUE

Truist Securities Initiates Coverage On Bluegreen Vacations with Buy Rating, Announces Price Target of $41

By Benzinga Newsdesk

Today, 5:08 AM

Truist Securities analyst Patrick Scholes initiates coverage on Bluegreen Vacations (NYSE:BVH) with a Buy rating and announces Price Target of $41.

BVH

Raymond James Maintains Outperform on PROG Holdings, Lowers Price Target to $55

By Benzinga Newsdesk

Today, 5:08 AM

Raymond James analyst Bobby Griffin maintains PROG Holdings (NYSE:PRG) with a Outperform and lowers the price target from $60 to $55.

PRG

Keybanc Downgrades Ballys to Sector Weight

Related Posts

JP Morgan Upgrades Continental Resources to Overweight, Announces $46 Price Target

FDA Okays bluebird bio’s $3M Gene Therapy For Rare Neurological Disorder In Boys: What Investors Should Know

Truist Securities Initiates Coverage On Bluegreen Vacations with Buy Rating, Announces Price Target of $41

Raymond James Maintains Outperform on PROG Holdings, Lowers Price Target to $55